Study Finds GLP-1 Receptor Agonists Enhance Glycemic Control and Promote Weight Loss in Children with Type 2 Diabetes

A recent comprehensive review published in JAMA Pediatrics highlights the positive effects of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in managing type 2 diabetes (T2D) and obesity among children and adolescents. The study analyzed data from 18 randomized controlled trials involving 1,402 participants, of whom 838 received GLP-1 RAs and 564 received a placebo.

The findings revealed that children treated with GLP-1 RAs experienced significant health improvements, including a reduction in hemoglobin A1c by 0.44%, fasting glucose levels by approximately 9.92 mg/dL, and notable weight loss of around 3.02 kg. There was also a decrease in body mass index (BMI), BMI z-scores, BMI percentiles, and systolic blood pressure, indicating overall enhancements in metabolic health.

While gastrointestinal side effects such as nausea and related issues were more common among treatment recipients, no significant increases in other adverse events—including suicidal thoughts or behaviors—were observed. The authors concluded that these results suggest GLP-1 RAs offer a promising therapeutic option for pediatric patients struggling with T2D and obesity. They emphasized that understanding the balance of benefits and risks can guide clinicians, caregivers, and patients in making informed treatment decisions.

This systematic review underscores the potential of GLP-1 receptor agonists to improve glycemic control and support weight management in young populations, marking an important development in pediatric metabolic health management.

For more details, see the full study: published in JAMA Pediatrics.